Three 4′‐(4‐Methylbenzoate‐benzyloxy)‐2,2′:6′,2′′‐terpyridine (MBBtpy), 4′‐(4‐Ethylbenzoate‐benzyloxy)‐2,2′:6′,2′′‐terpyridine (EBBtpy) and 4′‐(5‐(1,3‐Dimethylbenzoate)‐benzyloxy)‐2,2′:6′,2′′‐terpyridine (DMBBtpy) ligands and seven ruthenium(II) symmetrical [Ru(MBBtpy)2](PF6)2 (Ru1), [Ru(EBBtpy)2](PF6)2 (Ru2), [Ru(DMBBtpy)2](PF6)2 (Ru3) and unsymmetrical [Ru(MBBtpy)(EBBtpy)](PF6)2 (Ru4), [Ru(MBBtpy)(ttpy)](PF6)2 (Ru5), [Ru(MBBtpy)(Brttpy)](PF6)2 (Ru6), [Ru(MBBtpy)(HOttpy)](PF6)2 (Ru7) complexes were synthesized and characterized by UV/Vis, Fluorescence, FTIR, 1H & 13C NMR, ESI‐mass spectral studies and electrochemical studies. The crystal structure of HOttpy ligand was determined by single crystal X‐ray diffraction. The cyclic voltammograms of Ru(II) complexes exhibit a quasi‐reversible oxidation peak corresponding to RuII/RuIII process. The peak current Ipa and Ipc increases with increase in scan rate. The Ru(II) complexes tested for in vitro antimicrobial activity against four human pathogens and fungus Candida albicans showed good antibacterial and antifungal activity. The binding of Ru(II) complexes with calf thymus DNA was determined by UV/Vis spectroscopy. The cleavage activity of ruthenium(II) complexes studied by gel electrophoresis indicates that these complexes can cleave pUC19 DNA more efficiently when compared to that of control.